OpGen – executive interview

Published on 30 April 2020

OpGen is a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious diseases. Its development and commercialization of molecular microbiology solutions are aimed at providing actionable information about life-threatening infections to improve patient outcomes and decrease the spread of infections caused by multidrug-resistant microorganisms. On 1 April 2020, the company announced the closure of its business combination with Curetis. Oliver Schacht, president and CEO of OpGen, and Evan Jones, former chairman and CEO, talk through the details of the business combination, strategic initiatives and forthcoming milestones.

OpGen (OPGN), along with subsidiaries, Curetis and Ares Genetics, has a product portfolio that includes Unyvero, Acuitas AMR Gene Panel and Acuitas Lighthouse, and the ARES Technology Platform including ARESdb, using NGS technology and AI-powered bioinformatics solutions for antibiotic response prediction.

Share this with friends and colleagues